Opiate pharmacology and relief of pain

Journal of Clinical Oncology

Volumn 32, Issue 16, 2014, Pages 1655-1661

  Pasternak, Gavril W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; OPIATE;

ANALGESIA; ANALGESIC ACTIVITY; CANCER PAIN; CLINICAL EFFECTIVENESS; DRUG CROSS TOLERANCE; DRUG DEPENDENCE; DRUG MECHANISM; DRUG SEEKING BEHAVIOR; EVIDENCE BASED MEDICINE; HUMAN; INFLAMMATORY PAIN; LIGAND BINDING; LIMBIC SYSTEM; LOCUS CERULEUS; MOLECULAR BIOLOGY; NERVE FIBER; NEUROPATHIC PAIN; NONHUMAN; PATIENT CARE; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAPHE MAGNUS NUCLEUS; REVIEW; THALAMUS;

ANALGESICS, OPIOID; ANIMALS; HUMANS; PAIN;

EID: 84905858738     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.1079     Document Type: Review

References (51)

1. Payne R: Pathophysiology of cancer pain, in McDonald N, Doyle D, Hanks G (eds): Oxford Textbook of Medicine. London, United Kingdom, Oxford University Press, 1997
2. Payne R, Pasternak GW: Pain, in Johnston MV, Macdonald RL, Young AB (eds): Principles of Drug Therapy in Neurology. Philadelphia, PA, F.A. Davis, 1992, pp 268-301
3. Foley KM: Controlling the pain of cancer. Sci Am 275:164-165, 1996
4. Mogil JS, Ritchie J, Smith SB, et al: Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 42:583-587, 2005 (Pubitemid 40993835)
5. Rossi GC, Brown GP, Leventhal L, et al: Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia. Neurosci Lett 216:1-4, 1996 (Pubitemid 26321035)
6. Chang A, Emmel DW, Rossi GC, et al: Methadone analgesia in morphine-insensitive CXBK mice. Eur J Pharmacol 351:189-191, 1998 (Pubitemid 28312930)
7. Neilan CL, King MA, Rossi G, et al: Differential sensitivities of mouse strains to morphine and [Dmt1]DALDA analgesia. Brain Res 974:254-257, 2003 (Pubitemid 36549241)
8. Baran A, Shuster L, Eleftheriou BE, et al: Opiate receptors in mice: Genetic differences. Life Sci 17:633-640, 1975
9. Pasternak GW: Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 22:67-70, 2001
10. Pasternak GW, Pan YX: Mu opioids and their receptors: Evolution of a concept. Pharmacol Rev 65:1257-1317, 2013
11. Beecher HK: Pain in men wounded in battle. Ann Surg 123:96-105, 1946
12. Portenoy RK, Lesage P: Management of cancer pain. Lancet 353:1695-1700, 1999 (Pubitemid 29224537)
13. Reisine T, Pasternak GW: Opioid analgesics and antagonists, in Hardman JG, Limbird LE (eds): Goodman & Gilman's: The Pharmacological Basis of Therapeutics (ed 9). New York, NY, McGraw-Hill, 1996, pp 521-556
14. Mantyh P: Bone cancer pain: Causes, consequences, and therapeutic opportunities. Pain [epub ahead of print on July 31, 2013]
15. Elliott JA, Horton E, Fibuch EE: The endocrine effects of long-term oral opioid therapy: A case report and review of the literature. J Opioid Manag 7:145-154, 2011
16. Faskowitz AJ, Kramskiy VN, Pasternak GW: Methadone-induced hypoglycemia. Cell Mol Neurobiol 33:537-542, 2013
17. Maingi S, Moryl N, Andrew F: Symptomatic hypoglycemia due to escalating doses of intravenous methadone. J Pain 9:37, 2008
18. Wiederholt IC, Genco M, Foley JM: Recurrent episodes of hypoglycemia induced by propoxyphene. Neurology 17:703-706, 1967
19. Spiegel K, Kourides IA, Pasternak GW: Prolactin and growth hormone release by morphine in the rat: Different receptor mechanisms. Science 217:745-747, 1982 (Pubitemid 12049579)
20. Wei E, Loh HH, Way EL: Neuroanatomical correlates of morphine dependence. Science 177:616-617, 1972
21. Pert A, Yaksh T: Sites of morphine induced analgesia in primate brain: Relation to pain pathways. Brain Res 80:135-140, 1974
22. Fields HL, Martin JB: Pain: pathophysiology and management, in Braunwald E, Hauser SL, Fauci AS, et al (eds): Harrison's Principles of Internal Medicine (ed 15). New York, NY, McGraw-Hill, 2001, pp 55-60
23. Basbaum AI, Fields HL: Endogenous pain control systems: Brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7:309-338, 1984 (Pubitemid 14155301)
24. Yeung JC, Rudy TA: Multiplicative interaction between narcotic agonisms expressed at spinal and supraspinal sites of antinociceptive action as revealed by concurrent intrathecal and intracerebroventricular injections of morphine. J Pharmacol Exp Ther 215:633-642, 1980 (Pubitemid 11210370)
25. Rossi GC, Pasternak GW, Bodnar RJ: Synergistic brainstem interactions for morphine analgesia. Brain Res 624:171-180, 1993 (Pubitemid 23281817)
26. Kolesnikov Y, Pasternak GW: Topical opioids in mice: Analgesia and reversal of tolerance by a topical N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 290:247-252, 1999 (Pubitemid 29302327)
27. Kolesnikov YA, Jain S, Wilson R, et al: Peripheral morphine analgesia: Synergy with central sites and a target of morphine tolerance. J Pharmacol Exp Ther 279:502-506, 1996 (Pubitemid 27166819)
28. Weddel SJ, Ritter RR: Serum levels following epidural administration of morphine and correlation with relief of postsurgical pain. Anesthesiology 54:210-214, 1981 (Pubitemid 11154034)
29. Foley KM: Management of cancer pain in cancer, in DeVita VT, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology. New York, NY, Lippincott, 1985, pp 1940-1961
30. Cherny N, Ripamonti C, Pereira J, et al: Strategies to manage the adverse effects of oral morphine: An evidence-based report. J Clin Oncol 19:2542-2554, 2001 (Pubitemid 32391226)
31. Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation: Establishing "best practices" for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage 38:418-425, 2009
32. Ling GS, Spiegel K, Lockhart SH, et al: Separation of opioid analgesia from respiratory depression: Evidence for different receptor mechanisms. J Pharmacol Exp Ther 232:149-155, 1985 (Pubitemid 15193665)
33. Ling GS, MacLeod JM, Lee S, et al: Separation of morphine analgesia from physical dependence. Science 226:462-464, 1984 (Pubitemid 14012817)
34. Ling GS, Spiegel K, Nishimura SL, et al: Dissociation of morphine's analgesic and respiratory depressant actions. Eur J Pharmacol 86:487-488, 1983 (Pubitemid 13171535)
35. Violin JD, Lefkowitz RJ: Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28:416-422, 2007
36. Groer CE, Schmid CL, Jaeger AM, et al: Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. J Biol Chem 286:31731-31741, 2011
37. Raehal KM, Schmid CL, Groer CE, et al: Functional selectivity at the μ-opioid receptor: Implications for understanding opioid analgesia and tolerance. Pharmacol Rev 63:1001-1019, 2011
38. Kelly E: Efficacy and ligand bias at the μ-opioid receptor. Br J Pharmacol 169:1430-1446, 2013
39. Tidgewell K, Groer CE, Harding WW, et al: Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem 51:2421-2431, 2008 (Pubitemid 351628503)
40. DeWire SM, Yamashita DS, Rominger DH, et al: A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344:708-717, 2013
41. Chen Y, Mestek A, Liu J, et al: Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 44:8-12, 1993 (Pubitemid 23230453)
42. Eppler CM, Hulmes JD, Wang JB, et al: Purification and partial amino acid sequence of a mu opioid receptor from rat brain. J Biol Chem 268:26447-26451, 1993 (Pubitemid 23361722)
43. Thompson RC, Mansour A, Akil H, et al: Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron 11:903-913, 1993 (Pubitemid 23347475)
44. Wang JB, Imai Y, Eppler CM, et al: mu opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci U S A 90:10230-10234, 1993 (Pubitemid 23328286)
45. Manglik A, Kruse AC, Kobilka TS, et al: Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 485:321-326, 2012
46. Reiter E, Ahn S, Shukla AK, et al: Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52:179-197, 2012
47. Xu J, Xu M, Brown T, et al: Stabilization of the μ-opioid receptor by truncated single transmembrane splice variants through a chaperone-like action. J Biol Chem 288:21211-21227, 2013
48. Schuller AG, King MA, Zhang J, et al: Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2:151-156, 1999 (Pubitemid 30491315)
49. Pan YX, Xu J, Xu M, et al: Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci U S A 106:4917-4922, 2009
50. Majumdar S, Grinnell S, Le Rouzic V, et al: Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci U S A 108:19776-19783, 2011
51. Majumdar S, Subrath J, Le Rouzic V, et al: Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants. J Med Chem 55:6352-6362, 2012